Results
1 -
10 of
12Inhibition of protein-kinase-C u2014 dependent cell proliferation of human lung cancer cell lines by the dihydropyridine dexniguldipine, Journal of Cancer Research and Clinical Oncology In Vitro Modulation of Multidrug Resistance by BIBW22BS in Blasts of De Novo or Relapsed or Persistent AML, Acute Leukemias V Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial, Cancer Chemotherapy and Pharmacology Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model, Journal of Cancer Research and Clinical Oncology Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma, Journal of Cancer Research and Clinical Oncology Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo, Journal of Cancer Research and Clinical Oncology Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes u2014 first experience with their reversal, Annals of Hematology Secondary combined resistance to the multidrug-resistance-reversing activity of cyclosporin A in the cell line F4-6RADR-CsA, Journal of Cancer Research and Clinical Oncology Pharmacokinetics of the multidrug-resistance-converting drug dexniguldipine and its pyridine metabolite M-1 in the plasma, tumor, and renal tissue of tumor-bearing Wagu200a/u200aRij rats, Cancer Chemotherapy and Pharmacology In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia, Journal of Cancer Research and Clinical Oncology